this is the index
REFLECTIONS ON FDA CHANTIX HEARING
In mid October, the FDA convened a special meeting of drug safety and psycho-pharmacology experts to look at whether or not the smoking cessation drug Chantix needed to continue to carry a black box warning. […]
Oct, 31
ACT III: NOW THEY’RE PAYING PATIENTS TO GO TO THE FDA
Here’s the third installment of the saga about PR tactics on the “female sexual dysfunction” front as we get closer to the October 27/28 meeting on FSD and Patient-focused drug development. I (L.T.) first wrote […]
Oct, 14
Navigation
Please use the navigation to move within this section.
